US-based precision medicine company Tempus AI has acquired Deep 6 AI, an AI-powered precision research platform serving healthcare organisations and life sciences companies.
Founded in 2016, Deep 6 AI aims to bring life-saving treatments to patients faster by using AI in clinical trials, enabling healthcare organisations to de-risk trials, accelerate recruitment, and generate real-world evidence (RWE).
The company’s platform matches patients to clinical trials by mining real-time structured and unstructured electronic medical record (EMR) data across a broad ecosystem.
The ecosystem includes academic medical centres, National Cancer Institute (NCI)-Designated Cancer Centres, and NCI Community Oncology Research Programmes.
Deep 6 is integrated with more than 750 provider site locations, spanning more than 30 million patients, which will add to Tempus’ existing network.
Its Precision Research Ecosystem connects researchers, physicians, sponsors, and contract research organisations (CROs) to advance research.
For healthcare organisations, Deep 6 AI manages study feasibility requests in near real-time, reduces staff time searching through patient records and matches patients to clinical trials.
Its platform mines deep, real-time EMR data for pharmaceutical companies and research sites to understand the feasibility of running specific clinical trials, identify eligible patients, and generate RWE with speed and precision.
Tempus AI provides AI-enabled precision medicine solutions to help physicians deliver personalised patient care, enabling the discovery, development, and delivery of optimal therapeutics.
Tempus founder and CEO Eric Lefkofsky said: “Deep 6’s impressive integration infrastructure is well-suited to complement our connectivity efforts, which are central to our ability to support physicians in delivering optimised care for their patients.
“This acquisition broadens our reach, adding even more providers to our platform, and enhances our ability to deploy critical applications like Next, which helps physicians close care gaps, and TIME, which helps patients find potentially life-saving clinical trials.”
